ELITE 2020 Leader of the Future Merve Yilmaz of Bausch + Lomb

Merve Yilmaz

Product Manager, Ophthalmology Rx Marketing

Bausch + Lomb

Success Around the Globe

Merve Yilmaz, BSPharm, MBA, MS always knew she wanted to be a brand leader within the international pharmaceutical industry. Her goals were to successfully launch new global brands, understand the market needs, and build strategies to serve the community. She has thrived both in her native country Turkey, as well as in the United States, working at some of the largest pharmaceutical companies in both respective countries, and leading some of the biggest ophthalmology brands in the world.

For example, in 2017 at DEVA Pharmaceuticals, she led a Global Opinion Leader project for Dry Eye Disease (DED) treatment in order to raise awareness of DEPORES (cyclosporine ophthalmic emulsion) 0.05% use across Turkey. She managed this project over multiple cities to educate 500 ophthalmologists in new treatment protocols via a live broadcast in just a short period of time.

Shortly following the success of this project, Merve joined Abdi Ibrahim Pharmaceuticals, Turkey’s largest pharmaceutical company, which was new to the ophthalmology market. Executive management was impressed with Merve’s previous accomplishments and she became responsible for managing eight different brands, including two major brand launches within the ophthalmology field, DOLTE (loteprednol etabonate ophthalmic suspension) 0.5% and MOXIDEXA (moxifloxacin 0.5% and dexamethasone 0.1%).

Her experience as a pharmacist and as a marketing leader has contributed to her success both in Turkey and in her current role at Bausch + Lomb in the U.S., a leading global eye health business of Bausch Health Companies Inc., where her early accomplishments include successfully launching LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% (Bausch + Lomb). Merve’s unique clinical, marketing, and communication skills strategically align with her responsibilities while managing various other brands, such as PROLENSA® (bromfenac ophthalmic solution) 0.07% (Bausch + Lomb), targeting the ophthalmology and optometry markets.

She is proud of her accomplishments and her entrepreneurial spirit which will continue to set the foundation in her career growth at Bausch + Lomb and the pharmaceutical industry.


You May Also Like

PM360 2018 Trailblazer Awards Sponsors

Premier Brand Champion and Roundtable Sponsor Platinum Sponsors Gold Sponsors Silver Sponsor Official Public ...

PM360 2021 Trailblazer Awards Professional Website/Online Initiative Gold Winner BeyondSpring and Proximyl Health

CIN Risk Disease Awareness (BeyondSpring, Proximyl Health) Chemotherapy-induced neutropenia (CIN) is a common toxic ...